BRCA1 and ovarian carcinoma: The AZD6738 and olaparib combination is currently being tested in phase II trials, which includes the CAPRI study for recurrent ovarian cancers (NCT03462342), as well as OLAPCO study in patients with HR defects beyond those associated with BRCA1/2 mutations (NCT02576444).